Tony Berberabe | Authors

June 17, 2022

Patients with relapsed/refractory diffuse large B-cell lymphoma who benefit most from novel therapies vs patients who would likely do well with standard treatment were identified among all curatively treated patients in Sweden from 2007 to 2014.

May 24, 2022

Findings from a retrospective real world study conducted in patients with EGFR-mutated, stage IV non–small cell lung cancer from 4 Latin American countries showed a 66% frequency rate in molecular testing and a frequency of EGFR mutations of 22% overall.

March 25, 2022

The field of gynecologic cancer continues to leverage the role of immunotherapy and novel treatments to treat patients who have new diagnoses or who have recurrent disease.

March 24, 2022

Chimeric antigen receptor T cells manufactured using the Sleeping Beauty transposon in donor-derived cells and differentiated toward the cytokine-induced killer cell protocol induce a sustained response with minimal toxicities in patients with B-cell acute lymphoblastic leukemia.

January 22, 2022

Results from a large trial evaluating the combination of pembrolizumab and regorafenib showed durable results for patients with microsatellite stable colorectal cancer.

December 12, 2021

Analysis shows that International Prognostic Scoring System score and the presence of a JAK2 mutation was linked to risk of thrombosis in patients with primary myelofibrosis. Investigators observed a benefit for ruxolitinib in patients.